Quintrio
Home

Stock overview

Alpha Tau Medical Ltd. Ordinary Shares

DRTS

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Last trade $12.17
Day change +$0.195 (+1.63%)
Day range $11.69 – $12.64
Volume 819,601
Market cap $1.11B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for DRTS.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for DRTS.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16

Alpha Tau Medical reported positive interim results from its REGAIN trial testing Alpha DaRT for recurrent glioblastoma treatment. All eight treated patients remain alive with a median follow-up of 6.9 months, 100% objective response rate in six evaluable patients (83.3% complete responses), 100% treatment feasibility, and no unanticipated serious adverse events. The company plans to continue enrollment toward 20 patients.

GlobeNewswire Inc.

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau Medical Ltd. announced the completion of enrollment of 88 patients in its ReSTART pivotal trial for treating recurrent cutaneous squamous cell carcinoma (cSCC) with Alpha DaRT®. This marks the company's first completed U.S. pivotal study and a critical milestone toward FDA pre-market approval. The company has already initiated a modular PMA application process. Alpha DaRT has received Breakthrough Device Designation from the FDA for this indication.

GlobeNewswire Inc.

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

Alpha Tau Medical will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, discussing recent achievements and upcoming data milestones for their Alpha DaRT cancer therapy.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.